Gastrointestinal and Its Associated Malignancies: Diagnosis, Targets and Therapies—A Special Issue
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 15 May 2024 | Viewed by 101
Special Issue Editors
Interests: GI cancers; translational research; cancer therapeutics
Special Issue Information
Dear Colleagues,
Gastrointestinal cancers constitute a heterogenous and aggressive group of malignancies characterized by high relapse rates. They are ranked as the third-leading cause of cancer-related deaths, and this emphasizes the pressing need for advancements in both their diagnosis and treatment strategies. Unfortunately, a significant number of patients face late-stage diagnoses due to the unremarkable nature of early symptoms and the limited prevalence of regular screenings.
Diagnostic procedures include a range of techniques such as endoscopy, barium swallow, CT, NMR, PET/CT scans, and biomarker testing, as well as MRI with gadolinium and laparoscopy. This delayed identification, coupled with the constraints of available therapies, contributes to a grim prognosis, especially for individuals with advanced gastric cancer, resulting in a short lifespan of approximately one year. Standard treatment modalities involve radiotherapy, chemotherapy, and targeted therapy, yet their effectiveness is impeded by challenges like multi-drug resistance and tumor relapse.
Perioperative chemotherapy has emerged as the norm for resectable GI, while ongoing research explores the potential benefits of targeted therapy and immunotherapy across diverse clinical setups. Recent advancements in immunotherapy and biomarker-guided therapies offer optimism for enhanced outcomes, particularly in metastatic cases. The molecular classification of gastric cancer, utilizing biomarkers such as programmed cell death ligand 1 (PD-L1), microsatellite instability (MSI), and human epidermal growth factor receptor 2 (HER2), facilitates tailored treatment approaches. Molecular diagnostics play a pivotal role in characterizing genetic profiles, identifying potential molecular targets, and shaping personalized therapeutic strategies, representing the significant progress made in managing this intricate and challenging group of cancers.
Dr. Ganji P. Nagaraju
Dr. Seema Kumari
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- GI cancers
- oncogenesis
- diagnosis
- target identification
- biomarkers
- therapy
